Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Results From the Pivotal Phase 2b HERIZON-BTC-01 Study - Zanidatamab in Previously-Treated HER2‑Amplified Biliary Tract Cancer"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Shubham Pant
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Shubham Pant
Login to view comments.
Click here to Login